Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price target upped by stock analysts at Barclays from $329.00 to $341.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price target indicates a potential upside of 24.19% from the stock’s current price.
A number of other analysts have also commented on ASND. KeyCorp set a $330.00 price objective on Ascendis Pharma A/S in a research report on Friday. UBS Group boosted their price objective on Ascendis Pharma A/S from $269.00 to $315.00 and gave the stock a “buy” rating in a report on Friday. Citigroup cut their target price on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. Stifel Nicolaus reduced their target price on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Nineteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and an average price target of $314.10.
Read Our Latest Stock Analysis on ASND
Ascendis Pharma A/S Trading Down 0.3%
NASDAQ:ASND traded down $0.81 during trading hours on Monday, hitting $274.58. 58,985 shares of the stock were exchanged, compared to its average volume of 700,582. The company has a market capitalization of $17.13 billion, a P/E ratio of 17.97 and a beta of 0.40. The company has a quick ratio of 2.29, a current ratio of 2.89 and a debt-to-equity ratio of 0.25. The company’s 50 day moving average is $242.67 and its two-hundred day moving average is $239.83. Ascendis Pharma A/S has a twelve month low of $188.08 and a twelve month high of $282.15.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). The firm had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a net margin of 73.26% and a return on equity of 32.47%. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post 3.43 earnings per share for the current fiscal year.
Insider Activity at Ascendis Pharma A/S
In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the transaction, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 40.00% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Ascendis Pharma A/S
A number of hedge funds have recently modified their holdings of ASND. Chicago Partners Investment Group LLC grew its stake in shares of Ascendis Pharma A/S by 2.3% in the third quarter. Chicago Partners Investment Group LLC now owns 2,316 shares of the biotechnology company’s stock valued at $564,000 after buying an additional 52 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 69 shares in the last quarter. Fifth Third Bancorp raised its position in Ascendis Pharma A/S by 48.4% during the third quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 91 shares in the last quarter. ProShare Advisors LLC raised its position in Ascendis Pharma A/S by 5.6% during the third quarter. ProShare Advisors LLC now owns 2,134 shares of the biotechnology company’s stock worth $486,000 after acquiring an additional 113 shares in the last quarter. Finally, AlphaCentric Advisors LLC raised its position in Ascendis Pharma A/S by 2.6% during the third quarter. AlphaCentric Advisors LLC now owns 4,706 shares of the biotechnology company’s stock worth $1,072,000 after acquiring an additional 121 shares in the last quarter.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.
Recommended Stories
- Five stocks we like better than Ascendis Pharma A/S
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
